None

BG Medicine, Inc. Announces 510(k) Filing for the ARCHITECT Galectin-3 Assay on the Abbott ARCHITECT Automated Platform

WALTHAM, Mass, July 20, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, today announced the f...

BG Medicine seeks FDA clearence for ARCHITECT Galectin-3 assay

Cardiovascular diagnostics developer BG Medicine has filed a 510(k) Premarket Notification with the US Food and Drug Administration (FDA) for regulatory clearance for the ARCHITECT Galectin-3 assay.

Abbott's ARCHITECT Galectin-3 assay earns CE mark

Abbott today announced CE Marking (Conformite Europeenne) for the ARCHITECT Galectin-3 assay, a test to aid doctors in assessing the prognosis of patients diagnosed with chronic heart failure.

Abbott receives CE Mark for ARCHITECT HbA1c test

Abbott today announced CE Marking (Conformité Européenne) for the ARCHITECT clinical chemistry Hemoglobin A1c test, which may aid physicians in diagnosing and monitoring diabetes as well as identify...

Q&A: Architect of change

Urban campaigner and architect Arif Hasan has been central to a sanitary revolution, transforming Orangi, Karachi, from informal settlement to thriving community. Using his technical know-how, residen...

NJIT architect designs award-winning house that looks like an igloo

(New Jersey Institute of Technology) An NJIT College of Architecture and Design architect who designed an "ice house," reminiscent of an igloo, has received yet another award for his unique residence.

Harbor MedTech to launch Architect for skin wounds treatments

California-based medical device Harbor MedTech has gained FDA marketing approval for its first product, Architect, an advanced collagen matrix for treatment of partial and full thickness skin wounds.

Harbor MedTech to launch Architect for skin wounds treatment

California-based medical device Harbor MedTech has gained FDA marketing approval for its first product, Architect, an advanced collagen matrix for treatment of partial and full thickness skin wounds.

Determination of everolimus in blood samples from kidney and liver transplant recipients using the sirolimus chemiluminescence magnetic microparticle immunoassay (CMIA) on the Architect-i1000® System.

Background. There is significant immunoassay cross-reactivity between everolimus and sirolimus, and their routine determination using a common method may reduce the reagent costs. Methods. In 122 bloo...

Multicentric evaluation of two chemiluminescent immunoassays for IgG and IgM antibodies towards Rubella virus.

BACKGROUND: Screening and diagnosis of Rubella virus infection rely on testing for specific IgG and IgM. Immunoassays may yield different IgG results especially at low values, with difficulties in the...

Influence of sample type and delayed separation from cells on the measurement of B-type natriuretic peptide with the Architect system.

Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity.

Early detection of hepatitis C virus (HCV) is an important step in preventing progression to cirrhosis and hepatocellular carcinoma. Serologic assays for anti-hepatitis C (anti-HCV) antibody are valua...

Evaluation of two sirolimus assays using the ARCHITECT-i1000((R)) CMIA or RxL((R)) ACMIA methods in comparison with the IMx((R)) MEIA method.